Special Issue "Targeting Ras/RASSF in Cancer"

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 31 October 2019

Special Issue Editor

Guest Editor
Dr. Geoffrey J. Clark

Department of Pharmacology and Toxicology, University of Louisville, Louisville, United States
Website | E-Mail
Interests: RAS, RASSF, drug discovery, animal models

Special Issue Information

Dear Colleagues,

Ras is the most frequently inactivated tumor suppressor in human cancer. RASSF1A may be the most frequently inactivated tumor suppressor in human cancer. As RAS directly binds RASSF family proteins and uses them as pro-death effectors, the interaction of these proteins is likely to have a major effect on tumor phenotype and drug response. Indeed, in lung cancer patients, the worst prognosis tumors are almost always RAS+/RASSF1A. Moreover, RAS+/RASSF1A–transgenic mouse systems demonstrate enhanced tumorigenesis.

This issue considers novel therapeutic approaches that target RAS activation and/or RASSF protein inactivation. It includes studies describing novel inhibitor approaches, synthetic lethal and collateral lethal effects, rational drug combinations and drug resistance. It may also include more basic studies describing unique metabolic and signaling characteristics of RAS+/RASSF-tumors.  

Dr. Geoffrey J. Clark
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • RAS
  • synthetic lethal
  • collateral lethal
  • novel inhibitors
  • drug resistance

Published Papers

This special issue is now open for submission.
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top